Update on HIV Lipodystrophy

REFERENCES

• Hirsch MS, Steigbigel RI, Staszewski S, et al. Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV in-fection. Clin Infect Dis. 2003;37(8):1119–1124.
   PubMed Web of Science ®Google Scholar
• Blanch J, Rousaud A, Martinez E, et al. Impact of lipodys-trophy on the quality of life of HIV-1-infected patients. JAIDS. 2002;31(4):404–407.
   Google Scholar
• Power R, Tate HL, McGill SM, Taylor C. A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals. Sex Trans Inf. 2003;79(2):137–141.
   PubMed Web of Science ®Google Scholar
• Smith DE, Hudson J, Martin A, et al. Centralized assess-ment of dual-energy X-ray absorptiometry (DEXA) in multicenter studies of HIV-associated lipodystrophy. HIV Clin Trials. 2003;4(1):45–49.
   PubMed Web of Science ®Google Scholar
• Carr A, Law M. An objective lipodystrophy severity grad-ing scale derived from the lipodystrophy case definition score. JAIDS. 2003;33(5):571–576.
   Google Scholar
• Roth VR, Kravcik S, Angel JB. Development of a cervical fat pad following therapy with HIV-1 protease inhibitors. Clin Infect Dis. 1998;27:65–67.
   PubMed Web of Science ®Google Scholar
• Martin IP, Breen PA, Weigle DS. Absence of hypersensi-tivity to glucocoiticoids in antiretroviral-associated lipod-ystrophy. Obesity Res. 2003;11(1):21–24.
   PubMedGoogle Scholar
• Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS. 2003;17(7):971–979.
   PubMed Web of Science ®Google Scholar
• Dube MP, Zackin R, Yang Y, et al. Prospective study of regional body composition in antiretroviral-naive subjects randomized to receive zidovudine + lamivudine or didanosine + stavudine combined with nelfinavir, efavirenz, or both: A5005s, a substudy of ACTG 384. Antiviral Ther. 2002;7(3):L27.
   Web of Science ®Google Scholar
• Blanco F, Garcia-Benayas T, Jose de la Cruz J, Gonzalez-Lahoz J, Soriano V. First line therapy and mitochondrial damage: different nucleosides, different findings. HIV Clin Trials. 2003;4(1):11–19.
   PubMed Web of Science ®Google Scholar
• Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS. 2002; 16(18):2447–2454.
   PubMed Web of Science ®Google Scholar
• Murphy R, Katlama C, Weverling G-J, et al. Fat redistribu-tion and metabolic study (FRAMS) in patients receiving a nucleoside reverse transcriptase inhibitor, non- NRTI, or protease inhibitor-based regimen over 4 years: FRAMS!! substudy of the Atlantic study. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco. Abstract 718.
   Google Scholar
• Dube MP, Qian D, Edmondson-Melancon H, et al. Pro-spective, intensive study of metabolic changes associ-ated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis. 2002;35(4):475–481.
   PubMed Web of Science ®Google Scholar
• Sanne 1, Piliero P, Squires K, Thiry A, Schnittman S. Results of a phase 2 clinical trial at 48 weeks (A1424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. JAIDS. 2003;32(1):18–29.
   Google Scholar
• Cooper DA, Reiss P, Henry K, et al. The effects of enfuvirtide therapy on body composition and serum lipids through 48 weeks in the TORO trials. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco. Abstract 715.
   Google Scholar
• Powderly W, Cahn P, Raffi F, et al. Lipid abnormalities and body habitus in a double-blind, randomized, controlled trial comparing emtricitabine to stavudine in HIV+ ART-naive patients. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco. Abstract 717.
   Google Scholar
• Caso JA, Prieto J de M, Casas E, Sanz J. Gynecomastia without lipodystrophy syndrome in HIV-infected men treated with efavirenz. AIDS. 2001; 15(11):1447–1448.
   PubMed Web of Science ®Google Scholar
• Qazi NA, Morlese JF, King DM, et al. Gynaecomastia without lipodystrophy in HIV-1-seropositive patients on efavirenz: an alternative hypothesis. AIDS. 2002; 16(3):506–507.
   PubMed Web of Science ®Google Scholar
• Shimomura I, Hammer RE, Richardson JA, et al. Insulin resistance and diabetes mellitus in transgenic mice ex-pressing nuclear SREBP-lc in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev. 1998;12:3182–3194.
   PubMed Web of Science ®Google Scholar
• Agarwal AK, Garg A. A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab. 2002;87:408–411.
   PubMed Web of Science ®Google Scholar
• Hegele RA, Cao H, Frankowski C, Matthews ST, Leff T. PPARH F388L, a trans-activation-deficient mutant, in fa-milial partial lipodystyrophy. Diabetes. 2002;51:3586–3590.
   PubMed Web of Science ®Google Scholar
• Savage DB, Tan GD, Acerini CL, et al. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated re-ceptor-gamma. Diabetes. 2003;52:910–917.
   PubMed Web of Science ®Google Scholar
• Dowell P, Flexner C, Kwiterovich PO, Lanes MD. Sup-pression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J Biol Chem. 2000;275:41325–41332.
   PubMed Web of Science ®Google Scholar
• Bastard J-P, Caron M, Vidal H, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1 infected patients and abnormal adipocyte differentiation and insulin resis-tance. Lancet. 2002;359:1026–1031.
   PubMed Web of Science ®Google Scholar
• Kannisto K, Sutinen J, Korsheninnikova E, et al. Expres-sion of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystro-phy associated with highly active antiretroviral therapy. AIDS. 2003;17(12):1753–1762.
   PubMed Web of Science ®Google Scholar
• Domingo P, Matias-Guiu X, Pujol RM, et al. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associ-ated lipodystrophy. AIDS. 1999;13:2261–2267.
   PubMed Web of Science ®Google Scholar
• Brinkman K, Smeitink J, Romijn J, et al. Mitochondrial toxicity induced by nucleoside analogue reverse tran-scriptase inhibitors is a key factor in the pathogenesis of antiretroviral therapy related lipodystrophy. Lancet. 1999;354:1112–1115.
   PubMed Web of Science ®Google Scholar
• Shikuma C, Hu N, Milne C, et al. Mitochondria! DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS. 2001;15:1801–1809.
   PubMed Web of Science ®Google Scholar
• Kakuda T, Brundage R, Anderson PL, Fletcher CV. Nucleoside reverse transcriptase inhibitor-induced mito-chondrial toxicity as an etiology for lipodystrophy. AIDS. 111;13:2311-2312.
   Google Scholar
• Miura T, Goto M, Hosoya N, et al. Depletion of mitochon-dnal DNA in HIV-1 infected patients and its amelioration by antiretroviral therapy. J Med ViroL 2003;70(4):497–505.
   PubMed Web of Science ®Google Scholar
• Nolan D, Hammond E, Martin A, et al. Mitochondria! DNA depletion and morphologic changes in adipocytes associ-ated with nucleoside reverse transcriptase inhibitor therapy. AIDS. 2003;17(9):1329–1338.
   PubMed Web of Science ®Google Scholar
• Vigano A, Mora S, Brambilla P, et al. Impaired growth hormone secretion correlates with visceral adiposity in highly active antiretroviral-treated HIV-infected adoles-cents. AIDS. 2003;17(10):1435–1441.
   PubMed Web of Science ®Google Scholar
• Mynarcik D, McNurlan M, Steigbigel R, et al. Association of severe insulin resistance with both loss of limb fat and elevated serum tumour necrosis factor receptor levels in HIV lipodystrophy. JAIDS. 2000;25:312–321.
   Google Scholar
• Roubenoff R, Weiss L, McDermott A, et al. A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. AIDS. 1999;13(11):1373–1375.
   PubMed Web of Science ®Google Scholar
• Lafaurie M, Dolivo M, Boulu D, et al. Treatment of facial lipoatrophy with injections of polylactic acid in HIV-in-fected patients: results from a cohort of 94 patients. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco. Abstract 726.
   Google Scholar
• Lo JC, Mulligan K, Noor MA, et al. The effects of recombi-nant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat ac-cumulation. J Clin Endocrinol Metab. 2001;86(8):3480–3487.
   PubMed Web of Science ®Google Scholar
• He Q, Engelson ES, Albu JB, Heymsfield SB, Kotler DP. Preferential loss of omental-mesenteric fat during growth hormone therapy of HIV-associated lipodystrophy. J Appl PhysioL 2003;94(5):2051–2057.
   PubMed Web of Science ®Google Scholar
• Engelson ES, Glesby MJ, Mendez D, et al. Effect of re-combinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. JAIDS. 2002;30(4):379–391.
   Google Scholar
• Mauss S, Wolf E, Jaeger H. Reversal of protease inhibitor-related visceral abdominal fat accumulation with recombi-nant human growth hormone. Ann Intern Med. 1999;131(4):313–314.
   PubMed Web of Science ®Google Scholar
• Wanke C, Gerrior J, Kantaros J, Coakley E, Albrecht M. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS. 1999; 13(15):2099–2103.
   PubMed Web of Science ®Google Scholar
• Kotler DP, Grunfeld C, Muurahainen N, et al. Low-dose maintenance therapy with recombinant human growth hormone sustains effects of previous r-hGH treatment in HIV+ patients with excess center fat: treatment results at 60 weeks. In: Program and abstracts of the 11th Confer-ence on Retroviruses and Opportunistic Infections; 2004; San Francisco. Abstract 80.
   Google Scholar
• Ponce-de-Leon S, Iglesias M, Ceballos J, Ostrosky-Zeichner L. Liposuction for protease-inhibitor-associated lipodystrophy. Lancet. 1999; 353(9160):1244.
   PubMed Web of Science ®Google Scholar
• Piliero PJ, Hubbard M, King J, Faragon JJ. Use of ultra-sonography-assisted liposuction for the treatment of hu-man immunodeficiency virus-associated enlargement of the dorsocervical fat pad. Clin Infect Dis. 2003;37(10)1 374–1377.
   Web of Science ®Google Scholar
• Saint-Marc T, Touraine J L. Effects of metformin on insulin resistance and central adiposity in patients receiving ef-fective protease inhibitor therapy. AIDS. 1999;13:1000–1002.
   PubMed Web of Science ®Google Scholar
• Hadigan C, Corcoran C, Basgoz N, et al. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA. 2000;284:472–477.
   PubMed Web of Science ®Google Scholar
• Gelato MC, Mynarcik DC, Quick JL, et al. Improved insulin sensitivity and body fat distribution in HIV-infected pa-tients treated with rosiglitazone: a pilot study. JAIDS. 2002;31(2):163–170.
   Google Scholar
• Carr A, Workman C, Carey D, et al. No effect of rosiglitazone for treatment of HIV lipoatrophy: a random-ized double-blind, placebo-controlled trial. Lancet. 2004;363(9407):429–438.
   PubMed Web of Science ®Google Scholar
• Martinez E, Conget I, Lozano L, et al. Reversion of meta-bolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS. 1999;13:805–810.
   PubMed Web of Science ®Google Scholar
• Martinez E, Garcia-Viejo M, Blanco JL, et al. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis. 2000;31:1266–1273.
   PubMed Web of Science ®Google Scholar
• Walli R, Huster K, Bohner JR, et al. Switching from PI to ABC improves insulin sensitivity and fasting lipids - 12 month follow-up. In: Program and abstracts of the Eighth Conference on Retroviruses and Opportunistic Infections; 2001; Chicago. Abstract 672.
   Google Scholar
• Ruiz L, Negredo E, Domingo P, et al. Antiretroviral treat-ment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, random-ized, controlled study. JAIDS. 2001;27(3):229–236.
   Google Scholar
• Carr A, Hudson J, Chuah J, et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open label, multicentre study. AIDS. 2001;15:1811–1822.
   PubMed Web of Science ®Google Scholar
• Carr A, Workman C, Smith D, et al. Abacavir substitution for nucleoside analogues in patients with HIV lipoatrophy: a randomized trial. JAMA. 2002;288:207–215.
   PubMed Web of Science ®Google Scholar
• John M, McKinnon EJ, James IR, et al. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or re-verse lipoatrophy in HIV-infected patients. JAIDS. 2003;33(1):29–33.
   Google Scholar
• Moyle GJ, Baldwin C, Langroudi B, Mandalia S, Gazzard BG. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. JAIDS. 2003;33(1):22–28.
   Google Scholar
• McComsey GA, Ward DJ. Hessenthaler SM, et al. Im-provement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis. 2004;38:263–270.
   PubMed Web of Science ®Google Scholar
• Lafeuillade A, Clumeck N, Mallolas J, et al. Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus con-tinued HAART: the Trizal study. HIV Clin Trials. 2003;4(1):37–43.
   PubMed Web of Science ®Google Scholar
• Carr A, Miller J, Law M, et al. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 2000;14:F25–32.
   PubMed Web of Science ®Google Scholar
• Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemias in HIV-infected individuals treated with pro-tease inhibitors. Circulation. 1999;100:700–705.
   PubMed Web of Science ®Google Scholar
• Purnell JQ. Zambon A, Knopp RH, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal sub-jects. AIDS. 2000;14(1):51–57.
   PubMed Web of Science ®Google Scholar
• Behrens G, Schmidt HH, Stoll M, Schmidt RE. ApoE genotypeandprotease-inhibitor-associatedhyperlipidaemia. Lancet. 1999;354(9172):76.
   PubMed Web of Science ®Google Scholar
• Distler 0, Cooper DA, Deckelbaum RJ, Sturley SL. Hyper-lipidemia and inhibitors of HIV protease. Curr Op Clin Nutri Met Care. 2001;4(2):99–103.
   PubMed Web of Science ®Google Scholar
• Mooser V, Carr A. Antiretroviral therapy-associated hyperlipidaemia in HIV disease. Curr Op Lipid. 200112(3):313–319.
   Google Scholar
• Miserez AR, Muller PY, Barella L, et al. A single-nucleotide polymorphism in the sterol-regulatory element-binding protein lc gene is predictive of HIV-related hyperlipoproteinaemia. AIDS. 2001;15(15):2045–2049.
   PubMed Web of Science ®Google Scholar
• Reeds DN, Mittendorfer B, Patterson BW, Powderly WG, Yarasheski KE, Klein S. Alterations in lipid kinetics in men with HIV-dyslipidemia. Am J Physiol. 2003;285(3):E490–497.
   Web of Science ®Google Scholar
• Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS. 1999;13(10):F63–70.
   PubMed Web of Science ®Google Scholar
• Schmidt HH, Behrens G, Genschel J, et al. Lipid evalua-tion in HIV-1-positive patients treated with protease in-hibitors. Antivir Ther. 1999;4(3):163–170.
   PubMed Web of Science ®Google Scholar
• Liang JS, Distler O, Cooper DA, et al. HIV protease inhibi-tors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibi-tor-inducedhyperlipidemia. NatureMed.20017(12):1327–1331.
   Google Scholar
• Van der Valk M, Kastelein JJ, Murphy RL, et al. Nevirapine-containing antiretroviral therapy in HIV-1 in-fected patients results in an anti-atherogenic lipid profile. AIDS. 200115(18):2407–2414.
   Google Scholar
• Dube MP, Sprecher D, Henry WK, et al. Preliminary guide-lines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Infect Dis. 2000;31(5):1216–1224.
   PubMed Web of Science ®Google Scholar
• Henry K, Melroe J, Huebesch J, et al. Atorvastatin and gemfibrozil for protease inhibitor related lipid abnormali-ties. Lancet. 1998;352:1031–1032.
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Lloyd M, Reynolds B, et al. Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS. 200115(12):1503–1508.
   Google Scholar
• Fichtenbaum C, Gerber J, RosenKranz S, et al. Pharma-cokinetic interactions between protease inhibitors and selected HMG CoA reductase inhibitors. In: Program and abstracts of the Seventh Conference on Retroviruses and Opportunistic Infections; 2000; San Francisco. Abstract LB6.
   Google Scholar
• Sosman J, Merwood W, Bellehumeur JL, et al. Effects of pravastatin on lipoproteins and endothelial function in patients receiving HIV protease inhibitors. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco. Abstract 77.
   Google Scholar
• Aberg JA, Zackin RA, Evans SR, et al. A prospective, multi-center, randomized trial comparing the efficacy and safety of fenofibrate vs pravastatin in HIV-infected sub-jects with lipid abnormalities: final results of ACTG 5087. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco. Abstract 723.
   Google Scholar
• Miller J, Carr A, Brown D, et al. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridemia. In: Program and abstracts of the Eighth Conference on Retroviruses and Opportunistic Infections; 2001; Chicago. Abstract 540.
   Google Scholar
• De Luis DA, Aller R, Rachiller P, et al. Reversibility of severe hyperlipemia secondary to indinavir with micron-ized phenofibrate. Med Clin (Barc). 1999;113:716–717.
   PubMed Web of Science ®Google Scholar
• Thomas JC, Lopes-Virella MF, Del Bene VE, et al. Use of fenofibrate in the management of protease inhibitor-asso-ciated lipid abnormalities. Pharmacotherapy. 2000;20:727–734.
   PubMed Web of Science ®Google Scholar
• Wohl DA, Cunningham C, Tien H-C, et al. A randomized, open-label clinical trial of omega-3-fatty acid (fish oil) supplementation along with diet and exercise in HIV-infected patients with hypertriglyceridemia. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco. Abstract 724.
   Google Scholar
• Walli R, Mich! GM, Muhlbayer D, et al. Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. Res Esp Med (Berl). 2000;199:253–262.
   PubMedGoogle Scholar
• Casado JL, Arrizabalaga J, Antela A, et al. Long term efficacy and tolerance of switching the protease inhibitor for non-nucleoside reverse transcriptase inhibitors: a 52 week, multicenter, prospective study. In: Program and abstracts of the Eighth Conference on Retroviruses and Opportunistic Infections; 2001; Chicago. Abstract 673.
   Google Scholar
• Botella JI, Valero MA, Munoz V, et al. Complete resolution of protease inhibitor induced diabetes mellitus. Clin Endocrinol (Oxford). 2000;52:241–243.
   PubMed Web of Science ®Google Scholar
• Koppel K, Akerlund B, Sundstrom A, et al. Abnormal distribution of fat increases with time of exposure to NRTI-PI and the degree of hyperlipidaemia is similar in efavirenz and P1-treated patients [abstract P136]. 5th In-ternational Congress on Drug Therapy in HIV Infection. AIDS. 2000;14:55.
   Web of Science ®Google Scholar
• Tebas P, Yarasheski K, Henry K, et al. Evolution of mul-tiple metabolic parameters after the switch of protease inhibitors to nevirapine. In: Program and abstracts of the 13th International AIDS Conference; 2000; Durban. Ab-stract ThPpB1485.
   Google Scholar
• Bucher HC, Kofler A, Nuesch R, et al. Meta-analysis of randomized controlled trials of simplified versus contin-ued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients. AIDS. 2003;17:2451–2459.
   PubMed Web of Science ®Google Scholar
• Tsiodras S, Mantzoros C, Hammer S, et al. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5 year cohort study. Arch Intern Med. 2000;160:2050–2056.
   PubMed Web of Science ®Google Scholar
• Vigouroux C, Gharakhanjan S, Salhi Y, et al. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease. Diabetes Metab. 1999;25:383–392.
   PubMed Web of Science ®Google Scholar
• Shahmanesh M, Das S, Stolinski M, et al. Insulin resis-tance and apolipoprotein B kinetics: a comparison of protease inhibitor, efavirenz, or nevirapine-containing antiretroviral regimens. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic In-fections; 2004; San Francisco. Abstract 704.
   Google Scholar
• Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance and beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS. 1999;13:F63–70.
   PubMed Web of Science ®Google Scholar
• Dube MP, Johnson DL, Currier JS, et al. Protease inhibi-tor-associated hyperglycaemia. Lancet. 1997;350:713–714.
   PubMed Web of Science ®Google Scholar
• Sutinen J, Hakkinen AM, Westerbacka J, et al. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral-associated lipodystrophy. AIDS. 2002;16:2183–2193.
   PubMed Web of Science ®Google Scholar
• Sulkowski M, Mehta S, Moore R, Torbenson M, Chaisson R, Astemborski J, Thomas D. Population prevalence of hepatic steatosis among antiretroviral-experienced HCV/ HIV co-infected adults with and without stavudine ex-pose. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco. Abstract 72.
   Google Scholar
• Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS. 200115(7):F11–18.
   Google Scholar
• Walli R, Herfort O, Mich GM, et al. Treatment with pro-tease inhibitors associated with peripheral insulin resis-tance and impaired oral glucose tolerance in HIV-1-in-fected patients. AIDS. 1998;12(15):F167–173.
   PubMed Web of Science ®Google Scholar
• Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem. 2000;275:251–254.
   Web of Science ®Google Scholar
• Noor MA, Seneviratne T, Aweeka FT, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in hu-mans: a randomized, placebo-controlled study. AIDS. 2002;16(5):F1–8.
   PubMed Web of Science ®Google Scholar
• Murata H, Hruz PW, Mueckler M. Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concen-trations. AIDS. 2002;16(6):859–863.
   PubMed Web of Science ®Google Scholar
• Van der Valk M, Bisschop PH, Romijn JA, et al. Lipodys-trophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS. 200115(16):2093–2100.
   Google Scholar
• Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS. 1999;13(10):F63–70.
   PubMed Web of Science ®Google Scholar
• Dube MP, Edmondson-Melancon H, Qian D, et al. Pro-spective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients. JAIDS. 2001;27(2):130–134.
   Google Scholar
• Vigouroux C, Maachi M, Nguyen TH, et al. Serum adipocytokines are related to lipodystrophy and meta-bolic disorders in HIV-infected men under antiretroviral therapy. AIDS. 2003;17(10):1503–1511.
   PubMed Web of Science ®Google Scholar
• Addy CL, Gavrila A, Tsiodras S, Brodovicz K, Karchmer AW, Mantzoros CS. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat re-distribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab. 2003;88(2):627–636.
   PubMed Web of Science ®Google Scholar
• Sutinen J, Korsheninnikova E, Funahashi T, et al. Circulat-ing concentration of adiponectin and its expression in subcutaneous tissue in patients with highly active antiretroviral therapy-associated lipodystrophy. J Clin Endocrinol Metab. 2003; 88(4):1907–1910.
   PubMed Web of Science ®Google Scholar
• Behrens GM, Lloyd D, Schmidt HH, Schmidt RE, Trembath RC. Lessons from lipodystrophy: LMNA, en-coding lamin A/C, in HIV therapy-associated lipodystro-phy. AIDS. 2000;14(12)1 854–1855.
   Web of Science ®Google Scholar
• Carrillo-Jimenez R, Lamas GA, Hennekens CH. Thiazolidinediones could improve endothelial dysfunction and risk of premature coronary heart disease in HIV-infected patients. J Cardiovasc Pharmacol Therap. 2002;7(4):207–210.
   PubMedGoogle Scholar
• Oral EA, Simha V, Ruiz E, et al. Leptin replacement therapy for lipodystrophy. N Engl J Med. 2002;346:570–578.
   PubMed Web of Science ®Google Scholar
• Petersen KF, Oral EA, Dufour S, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest. 2002;109:1345–1350.
   PubMed Web of Science ®Google Scholar
• Simha V, Szczepaniak LS, Wagner AJ, DePaoli AM, Garg A. Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. Diabetes Care. 2003;26:30–35.
   PubMed Web of Science ®Google Scholar
• Noor M, Grasela D, Parker R, et al. The effect of atazanavir vs. lopinavir/ritonavir on insulin-stimulated glucose dis-posal rate in healthy subjects. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco. Abstract 702.
   Google Scholar
• Jones SP, Waitt CJ, Black DJ, Pirmohamed M. Effect of NRTI and PI on TNF-a and adiponectin mRNA expression in isolated subcutaneous and omental mature human adipocytes. In: Program and abstracts of the 11th Confer-ence on Retroviruses and Opportunistic Infections; 2004; San Francisco. Abstract 707.
   Google Scholar
• Cattelan AM, Trevenzoli M, Sasset L, et al. Indinavir and systemic hypertension. AIDS. 2001;15(6):805–807.
   PubMed Web of Science ®Google Scholar
• Bergersen BM, Sandvik L, Dunlop 0, Birkeland K, Bruun JN. Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naive and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Micro Infect Dis. 2003;22(12):731–736.
   PubMed Web of Science ®Google Scholar
• Thiebaut R, El-Sadr W, Chenuc G, et al. Predictors of hypertension and changes in blood pressure in HIV-in-fected patients in the D:A:D study. In: Program and ab-stracts of the 11th Conference on Retroviruses and Op-portunistic Infections; 2004; San Francisco. Abstract 75.
   Google Scholar
• Khalsa A, Karim P, Mack W, et al. Hypertension in HIV-infected women related to HAART: women's interagency HIV study. In: Program and abstracts of the 11th Confer-ence on Retroviruses and Opportunistic Infections; 2004; San Francisco. Abstract 741.
   Google Scholar
• Sattler FR, Qian D, Louie S, et al. Elevated blood pressure in subjects with lipodystrophy. AIDS. 2001;15(15):2001–2010.
   PubMed Web of Science ®Google Scholar
• Chow DC, Souza SA, Chen R, et al. Elevated blood pres-sure in HIV-infected individuals receiving highly active antiretroviral therapy. HIV Clin Trials. 2003;4(6):411–416.
   PubMed Web of Science ®Google Scholar
• Gray RP, Yudkin JS, Patterson DL, et al. Enzymatic evi-dence of impaired fibrinolysis in diabetic patients after thrombolytic therapy for acute myocardial infarction: a role for plasminogen activator inhibitor? Brit Heart J. 1993;70:530-536.
   Google Scholar
• Hamsten A, Iselius L, de Faire U, et al. Genetic and cultural inheritance of plasma fibrinogen concentration. Lancet. 1987;2:988–991.
   PubMed Web of Science ®Google Scholar
• Juhan-Vague I, Alessi MC. Plasminogen activator inhibi-tor 1 and atherothrombosis. Thromb Haemost. 1993;70:138–143.
   PubMed Web of Science ®Google Scholar
• Bastard JP, Pieroni L, Hainque B. Relationship between plasminogen activator inhibitor 1 and insulin resistance. Diabetes Metab Res Rev. 2000;16:192–201.
   PubMed Web of Science ®Google Scholar
• Hadigan C, Meigs JB, Rabe J, et al. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab. 2001;86:939–943.
   PubMed Web of Science ®Google Scholar
• Egger M. Cardiovascular epidemiology in the context of HIV disease. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000; Toronto. Abstract 1374.
   Google Scholar
• Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med. 2003;348(8):702–710.
   PubMed Web of Science ®Google Scholar
• Louie JK, Hsu LC, Osmond DH, Katz MH, Schwarcz SK. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998. J Infect Dis. 2002;186(7):1023–1027.
   PubMed Web of Science ®Google Scholar
• Iloeje U, Yuan Y, L'Italien G, et al. Protease inhibitor exposure time and risk of cardiovascular disease in HIV-infected patients. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco. Abstract 736.
   Google Scholar
• Barbaro G, Di Lorenzo G, Cirelli A, et al. An open-label, prospective, observational study of the incidence of coro-nary artery disease in patients with HIV infection receiving highly active antiretroviral therapy. Clin Therapeutics. 2003;25(9):2405–2418.
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349(21):1993–2003.
   PubMed Web of Science ®Google Scholar
• Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003;17:2479–2486.
   PubMed Web of Science ®Google Scholar
• Klein D, Hurley L, Quesenberry C, Sidney S. Hospitaliza-tion for coronary heart disease and myocardial infarction among northern California men with HIV-1 infection: addi-tional follow-up. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco. Abstract 739.
   Google Scholar
• Braitstein P, Yip B, Heath KV, et al. Interventional cardio-vascular procedures among HIV-infected individuals on antiretroviraltherapy1995-2000.AIDS.2003; 17(14):2071–2075.
   PubMed Web of Science ®Google Scholar
• Boccara F, Odi G, Teiger E, et al. Coronary revascularization in HIV-infected patients with coronary artery disease: a multicenter case control study. In: Pro-gram and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco. Abstract 740.
   Google Scholar
• Scribner AN, Troia-Cancio PV, Cox BA, et al. Osteonecro-sis in HIV: a case-control study. JAIDS. 2000;25(1):19–25.
   Google Scholar
• Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving po-tent antiretroviral therapy. AIDS. 2000;14:F63–67.
   PubMed Web of Science ®Google Scholar
• McDermott AY, Shevitz A, Knox T, et al. Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women. Am J Clin Nutritr. 2001;74(5):679–686.
   PubMed Web of Science ®Google Scholar
• Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2003;36(4):482–490.
   PubMed Web of Science ®Google Scholar
• Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS. 2003; 17(13):1917–1923.
   PubMed Web of Science ®Google Scholar
• McComsey G, Huang J, Woolley I, et al. Fragility fractures in HIV-infected subjects, an area for improvement. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco. Abstract 743.
   Google Scholar
• Carr A, Miller J, Eisman JA, Cooper DA. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS. 200115(6):703–709.
   Google Scholar
• Dusso A, Vidal M, Powderly WG, Yarasheshki KE, Tebas P. Protease inhibitors inhibit in vitro conversion of 25(OH)-vitamin D to 1,25(OH)2-vitamin D. In: Program and ab-stracts of the Second International Workshop on Adverse Drug Reactions and Lipodystrophy; 2000; Toronto. Ab-stract 030.
   Google Scholar
• Wang M, Teitelbaum SL, Tebas P, Powderly WG, Ross FP. Indinavir inhibits bone formation while ritonavir inhib-its osteoclast differentiation and function. In: Program and abstracts of the Eighth Conference on Retroviruses and Opportunistic Infections; 2001; Chicago. Abstract 541.
   Google Scholar
• Guaraldi G, Orlandi G, Madeddu G, et al. Alendronate reduces bone turnover in HIV-associated osteopenia and osteoporosis. In: Program and abstracts of the 11th Con-ference on Retroviruses and Opportunistic Infections; 2004; San Francisco. Abstract 742.
   Google Scholar
• Olano JP, Borucki MJ, Wen JW. Massive hepatic steato-sis and lactic acidosis in a patients with AIDS who was receiving zidovudine. Clin Infect Dis. 1995;21:973–976.
   PubMed Web of Science ®Google Scholar
• Lai KK, Gang DL, Zawacki JK, Cooley TP. Fulminant hepatic failure associated with 2',3'-dideoxyinosine (dd I). Ann Intern Med. 1991115: 283–284.
   Google Scholar
• Lenzo NP, Garas BA, French MA. Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV-infected patients: a case report. AIDS. 1997;11:1294–1296.
   PubMed Web of Science ®Google Scholar
• Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analgogue combination regimens. Clin Infect Dis. 2000;31(1):162–166.
   PubMed Web of Science ®Google Scholar
• John M, Moore CB, James IR, et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS. 200115: 717–723.
   Google Scholar
• Delgado J, Harris M, Tesiorowski A, Montaner JSG. Symptomatic elevations of lactic acid and their response to treatment manipulation in HIV infected individuals - a case series. Clin Infect Dis. 2001;33:2072–2074.
   PubMed Web of Science ®Google Scholar
• Antoniou T, Weisdorf T, Gough K. Symptomatic hyperlactatemia in an HIV-positive patient: a case report and discussion. CMAJ. 2003;168(2):195–198.
   PubMed Web of Science ®Google Scholar
• Lewis W, Dalakais MC. Mitochondrial toxicity of antiviral drugs. Nat Med. 1995;1:417–421.
   PubMed Web of Science ®Google Scholar
• Walker UA, Bauerle J, Laguno M, et al. Depletion of mitochondria! DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology. 2004;39(2):311–317.
   PubMed Web of Science ®Google Scholar
• Miro O, Lopez S, Martinez E, et al. Reversible mitochon-drial respiratory chain impairment during symptomatic hyperlactatemia associated with antiretroviral therapy. AIDS Res Hum Retrovirus. 2003;19(11):1027–1032.
   PubMed Web of Science ®Google Scholar
• Montaner JS, Cote HC, Harris M, et al. Nucleoside-related mitochondrial toxicity among HIV-infected patients re-ceiving antiretroviral therapy: insights from the evaluation of venous lactic acid and peripheral blood mitochondria! DNA. Clin Infect Dis. 2004;38\(suppl 2):573–79.
   Google Scholar
• Fouty B, Frerman F, Reves R. Riboflavin to treat nucleo-side analogue-induced lactic acidosis. Lancet. 1998;352:291–292.
   PubMed Web of Science ®Google Scholar
• Schramm C, Wanitschke R, Galle PR. Thiamine for the treatment of nucleoside analogue-induced severe lactic acidosis. Eur J AnaesthesioL 1999;16:733–735.
   PubMed Web of Science ®Google Scholar
• Brinkman K, Vrouenraets S, Kauffmann R, Weigel H, Frissen J. Treatment of reverse transcriptase inhibitor-induced lactic acidosis. AIDS. 2000;14:2801–2802.
   PubMed Web of Science ®Google Scholar